Connect Biopharma Holdings Ltd. (CNTB) intrinsic value & 10-year financials
Connect Biopharma Holdings Ltd. (CNTB) has a Graham intrinsic value of $164.78 per share. At $0.91 on Oct 17, 2026, the stock trades 99% below that value. Over the last 4 fiscal years revenue shrank 99.8% a year to $64.0K, with an average return on invested capital of 211.8%.
- Graham intrinsic value
- $164.78
- Share price (Oct 17, 2026)
- $0.91
- Price vs Graham value
- 99% below
- Market cap
- $50.4M
- Revenue (FY2025)
- $64.0K
- Revenue growth (4-yr CAGR)
- -99.8%
- ROIC (10-yr avg)
- 211.8%
- Free cash flow (FY2025)
- -$51.6M
CNTB 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $64.0K | -$55.5M | -$1.00 | -$51.6M | -90740.6% | -646.7% |
| FY2024 | $26.0M | -$15.6M | -$0.28 | -$24.4M | -86.2% | -450.3% |
| FY2023 | $0 | -$62.1M | -$1.13 | -$47.8M | — | 1732.5% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Connect Biopharma Holdings Ltd revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Connect Biopharma Holdings Ltd has historically struggled to out-earn its cost of capital, averaging just 2.1% ROIC.
Connect Biopharma Holdings Ltd capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Connect Biopharma Holdings Ltd is modeled at -99.8% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $164.78 per share.